Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Elicio Therapeutics, Inc.ANGN · Entity 299 | See Remarks | March 02, 2022 | March 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Elicio Therapeutics, Inc.
Report date March 02, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.99 · Expires 2032-03-01 | Direct | 175,000 |
Reported balance
After 2022-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-02 · Grant · Acquired 175,000 · Balance 175,000 F1: The total number of options vest in forty-eight (48) successive and equal monthly installments as measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.99 · Expires 2032-03-01 | Direct | 275,000 |
Reported balance
After 2022-03-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-02 · Grant · Acquired 100,000 · Balance 275,000 F2: The total number of options vest in equal parts on July 31, 2022 and December 31, 2022, such that 100% of the options will be fully vested and exercisable on December 31, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The total number of options vest in forty-eight (48) successive and equal monthly installments as measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F2: The total number of options vest in equal parts on July 31, 2022 and December 31, 2022, such that 100% of the options will be fully vested and exercisable on December 31, 2022.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
KERYX BIOPHARMACEUTICALS INC
Report date December 12, 2018 · Filed December 13, 2018
Section 16 reporting ended · disclosed 2018-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-12 transaction · row 1
1 source rowRow 1 · 2018-12-12 · Disposition to issuer · Disposed 148,279 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement. F2: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 66,039 shares of restricted stock, the vesting of which was accelerated as a result of a termination of the reporting person's employment in connection with the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. |
| Stock OptionSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-12-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-12-12 · Disposition to issuer · Disposed 772,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement.
F2: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 66,039 shares of restricted stock, the vesting of which was accelerated as a result of a termination of the reporting person's employment in connection with the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018.
F3: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2022 Filed Mar 4, 2022 16:21 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001601485-22-000013 · wf-form4_164642889806390.xml · derivative · entry 2 Neylan John F. · CIK 0001640447 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 100,000 shares Expires 2032-03-01 F2 · derivative.exercise_date: The total number of options vest in equal parts on July 31, 2022 and December 31, 2022, such that 100% of the options will be fully vested and exercisable on December 31, 2022. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 16:21 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001601485-22-000013 · wf-form4_164642889806390.xml · derivative · entry 1 Neylan John F. · CIK 0001640447 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2032-03-01 F1 · derivative.exercise_date: The total number of options vest in forty-eight (48) successive and equal monthly installments as measured from March 3, 2022 (the "Vesting Commencement Date"), such that 100% of the options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 16:25 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 358 | $2.62 | $938.00 |
DisclosureSEC source: 0001601485-21-000091 · wf-form4_164012191372345.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,136 F1 · kind: The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted on March 18, 2021 by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Awards ("RSAs") granted by the Issuer. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 19:09 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 374 | $4.13 | $1,544.62 |
DisclosureSEC source: 0001601485-21-000077 · wf-form4_163762613730453.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,494 F1 · kind: The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted on March 18, 2021 by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Awards ("RSAs") granted by the Issuer. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 17:06 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 373 | $8.62 | $3,215.26 |
DisclosureSEC source: 0001601485-21-000062 · wf-form4_163476398271611.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,868 F1 · kind: The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Awards ("RSAs") granted by the Issuer. Read SEC document |
| September 20, 2021 Filed Sep 21, 2021 16:32 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 376 | $10.07 | $3,786.32 |
DisclosureSEC source: 0001601485-21-000058 · wf-form4_163225630889400.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,241 F1 · kind: The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Awards ("RSAs") granted by the Issuer. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.07 to $10.09 inclusive. Read SEC document |
| August 18, 2021 Filed Aug 19, 2021 16:06 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 381 | $9.03 | $3,440.43 |
DisclosureSEC source: 0001601485-21-000052 · wf-form4_162940355890439.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,617 F1 · kind: The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Awards ("RSAs") granted by the Issuer. Read SEC document |
| July 21, 2021 Filed Jul 22, 2021 18:04 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 365 | $10.98 | $4,007.70 |
DisclosureSEC source: 0001601485-21-000038 · wf-form4_162699140642124.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,998 F1 · kind: The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Awards ("RSAs") granted by the Issuer. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 16:05 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 366 | $13.20 | $4,831.20 |
DisclosureSEC source: 0001601485-21-000029 · wf-form4_162430591954382.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,363 F1 · kind: The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Awards ("RSAs") granted by the Issuer. Read SEC document |
| May 18, 2021 Filed May 19, 2021 17:10 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 363 | $13.91 | $5,049.33 |
DisclosureSEC source: 0001601485-21-000025 · wf-form4_162145860149330.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,729 F1 · kind: The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Awards ("RSAs") granted by the Issuer. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 17:19 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 381 | $13.55 | $5,162.55 |
DisclosureSEC source: 0001601485-21-000013 · wf-form4_161895358056958.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,092 F1 · kind: The shares reported in this Form 4 were sold pursuant to a 10b5-1 trading plan adopted by the reporting person solely to satisfy tax or other government withholding obligations in connection with the vesting of shares of Restricted Stock of the Issuer. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 16:06 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 442 | $19.13 | $8,455.46 |
DisclosureSEC source: 0001567619-21-006685 · doc1.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,453 F1 · kind: The shares were sold to the Issuer solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a Restricted Stock Awards ("RSAs") of the Issuer. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 12:59 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 70,012 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001567619-21-002413 · doc1.xml · derivative · entry 1 Neylan John F. · CIK 0001640447 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,012 Underlying: Common Stock · 70,012 shares Expires 2031-02-03 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 4, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 16:33 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | Disposition to issuerStock Option · Derivative | 772,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030881 · doc4.xml · derivative · entry 2 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 772,500 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. F3 · price: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 16:33 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | Disposition to issuerCommon Stock | 148,279 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030881 · doc4.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement. F2 · shares: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 66,039 shares of restricted stock, the vesting of which was accelerated as a result of a termination of the reporting person's employment in connection with the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. F1 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement. F2 · price: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 66,039 shares of restricted stock, the vesting of which was accelerated as a result of a termination of the reporting person's employment in connection with the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 08:49 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,156 | $2.77 | $3,202.12 |
DisclosureSEC source: 0001114220-18-000110 · wf-form4_154237617523458.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,279 F1 · shares: Sale of a total of 1,156 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,063 shares of restricted stock on November 14, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 66,039 shares of restricted stock. Read SEC document |
| October 29, 2018 Filed Oct 30, 2018 16:07 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,253 | $3.07 | $3,846.71 |
DisclosureSEC source: 0001114220-18-000100 · wf-form4_154093005033411.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,435 F1 · shares: Sale of a total of 1,253 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on October 28, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 70,102 shares of restricted stock. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 07:10 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,186 | $3.04 | $3,605.44 |
DisclosureSEC source: 0001114220-18-000093 · wf-form4_153441783359781.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,688 F1 · shares: Sale of a total of 1,186 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,063 shares of restricted stock on August 14, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 74,581 shares of restricted stock. Read SEC document |
| July 30, 2018 Filed Jul 31, 2018 16:34 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,282 | $3.86 | $4,948.52 |
DisclosureSEC source: 0001114220-18-000086 · wf-form4_153306926524689.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,874 F1 · shares: Sale of a total of 1,282 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on July 28, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 78,644 shares of restricted stock. Read SEC document |
| May 15, 2018 Filed May 16, 2018 16:40 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,158 | $5.69 | $6,589.02 |
DisclosureSEC source: 0001114220-18-000055 · wf-form4_152650321264174.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,156 F1 · price: Sale of a total of 1,158 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,063 shares of restricted stock on May 14, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 83,123 shares of restricted stock. Read SEC document |
| April 30, 2018 Filed May 1, 2018 16:14 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,311 | $4.67 | $6,122.37 |
DisclosureSEC source: 0001114220-18-000046 · wf-form4_152520565539406.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,314 F1 · price: Sale of a total of 1,311 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on April 27, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 87,186 shares of restricted stock. Read SEC document |
| April 23, 2018 Filed Apr 24, 2018 16:29 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,111 | $4.59 | $5,099.49 |
DisclosureSEC source: 0001114220-18-000041 · wf-form4_152460173663254.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,625 F1 · price: Sale of a total of 1,111 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 3,749 shares of restricted stock on April 20, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 91,665 shares of restricted stock. Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 17:30 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | GrantStock Options (right to buy) · Derivative | 82,500 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001114220-18-000034 · wf-form4_152175422140887.xml · derivative · entry 2 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2028-03-20 F3 · derivative.exercise_date: The stock options vest according to the following schedule: one-third of the 82,500 options will vest on March 20, 2019 and one-twelfth will vest on each of June 20, 2019, September 20, 2019, December 20, 2019, March 20, 2020, June 20, 2020, September 20, 2020, December 20, 2020 and March 20, 2021. Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 17:30 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | GrantCommon Stock | 41,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001114220-18-000034 · wf-form4_152175422140887.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,736 F1 · shares: The 41,250 shares are restricted common stock, with one-third of the 41,250 shares vesting on March 20, 2019 and one-twelfth vesting on each of June 20, 2019, September 20, 2019, December 20, 2019, March 20, 2020, June 20, 2020, September 20, 2020, December 20, 2020 and March 20, 2021. F1 · price: The 41,250 shares are restricted common stock, with one-third of the 41,250 shares vesting on March 20, 2019 and one-twelfth vesting on each of June 20, 2019, September 20, 2019, December 20, 2019, March 20, 2020, June 20, 2020, September 20, 2020, December 20, 2020 and March 20, 2021. F2 · balance_after: Includes 95,414 shares of restricted stock. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 16:04 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 5,652 | $4.81 | $27,186.12 |
DisclosureSEC source: 0001114220-18-000022 · wf-form4_151881505408745.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,486 F1 · price: Sale of a total of 5,652 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 16,251 shares of restricted stock on February 14, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 54,164 shares of restricted stock. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 17:19 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,541 | $4.81 | $7,412.21 |
DisclosureSEC source: 0001114220-18-000014 · wf-form4_151743713508590.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,138 F1 · price: Sale of a total of 1,541 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on January 26, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 70,415 shares of restricted stock. Read SEC document |
| January 23, 2018 Filed Jan 24, 2018 16:16 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,322 | $4.92 | $6,504.24 |
DisclosureSEC source: 0001114220-18-000008 · wf-form4_151682858026825.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,679 F1 · price: Sale of a total of 1,322 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 3,749 shares of restricted stock on January 22, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 74,894 shares of restricted stock. Read SEC document |
| October 30, 2017 Filed Oct 31, 2017 16:12 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,405 | $6.03 | $8,472.15 |
DisclosureSEC source: 0001114220-17-000042 · wf-form4_150948072238816.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,001 F1 · price: Sale of a total of 1,405 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on October 27, 2017. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 78,643 shares of restricted stock. Read SEC document |
| October 23, 2017 Filed Oct 24, 2017 16:21 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,179 | $6.53 | $7,698.87 |
DisclosureSEC source: 0001114220-17-000034 · wf-form4_150887645896227.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,406 F1 · price: Sale of a total of 1,179 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 3,749 shares of restricted stock on October 20, 2017. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 83,122 shares of restricted stock. Read SEC document |
| July 31, 2017 Filed Aug 1, 2017 16:25 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,445 | $7.14 | $10,317.30 |
DisclosureSEC source: 0001114220-17-000020 · wf-form4_150161913493860.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,585 F1 · price: Sale of a total of 1,445 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on July 28, 2017. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 86,871 shares of restricted stock. Read SEC document |
| July 24, 2017 Filed Jul 25, 2017 17:00 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,214 | $7.27 | $8,825.78 |
DisclosureSEC source: 0001114220-17-000013 · wf-form4_150101640651405.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,030 F1 · price: Sale of a total of 1,214 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 3,750 shares of restricted stock on July 21, 2017. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 91,350 shares of restricted stock. Read SEC document |
| May 01, 2017 Filed May 3, 2017 16:05 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,441 | $5.97 | $8,602.77 |
DisclosureSEC source: 0000899243-17-011612 · doc4.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,244 F1 · price: Sale of a total of 1,441 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,480 shares of restricted stock on April 28, 2017. Mr. Neylan had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 95,100 shares of restricted stock. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 16:05 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,209 | $5.73 | $6,927.57 |
DisclosureSEC source: 0000899243-17-010904 · doc4.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,685 F1 · price: Sale of a total of 1,209 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 3,750 shares of restricted stock on April 21, 2017. Mr. Neylan had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 99,580 shares of restricted stock. Read SEC document |
| February 14, 2017 Filed Mar 15, 2017 18:31 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | GrantEmployee Stock Option (Right to Buy) · Derivative | 97,500 | $0.00 Strike: $5.53 | $0.00 |
DisclosureSEC source: 0000899243-17-007648 · doc4.xml · derivative · entry 2 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,500 Underlying: Common Stock · 97,500 shares Expires 2027-02-14 F3 · derivative.exercise_date: The options vest according to the following schedule: one-third of the 97,500 options will vest on February 14, 2018 and one-twelfth will vest on each of May 14, 2018, August 14, 2018, November 14, 2018, February 14, 2019, May 14, 2019, August 14, 2019, November 14, 2019 and February 14, 2020. Read SEC document |
| February 14, 2017 Filed Mar 15, 2017 18:31 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | GrantCommon Stock | 48,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-007648 · doc4.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,894 F1 · shares: The 48,750 shares are restricted common stock, with one-third of the 48,750 shares vesting on February 14, 2018 and one-twelfth vesting on each of May 14, 2018, August 14, 2018, November 14, 2018, February 14, 2019, May 14, 2019, August 14, 2019, November 14, 2019 and February 14, 2020. F1 · price: The 48,750 shares are restricted common stock, with one-third of the 48,750 shares vesting on February 14, 2018 and one-twelfth vesting on each of May 14, 2018, August 14, 2018, November 14, 2018, February 14, 2019, May 14, 2019, August 14, 2019, November 14, 2019 and February 14, 2020. F2 · balance_after: Includes 103,330 shares of restricted stock. Read SEC document |
| January 30, 2017 Filed Jan 31, 2017 16:05 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 6,984 | $4.65 | $32,475.60 |
DisclosureSEC source: 0000899243-17-002275 · doc4.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,144 F1 · price: Sale of a total of 6,984 shares of common stock was made in order to satisfy Dr. Neylan's income tax withholding obligation upon the vesting of 17,917 shares of restricted stock on January 27, 2017. Dr. Neylan had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 54,583 shares of restricted stock. Read SEC document |
| January 23, 2017 Filed Jan 25, 2017 16:06 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,428 | $5.39 | $7,696.92 |
DisclosureSEC source: 0000899243-17-001941 · doc4.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,128 F1 · price: Sale of a total of 1,428 shares of common stock was made in order to satisfy Dr. Neylan's income tax withholding obligation upon the vesting of 3,750 shares of restricted stock on January 22, 2017. Dr. Neylan had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 72,500 shares of restricted stock. Read SEC document |
| October 24, 2016 Filed Oct 25, 2016 16:05 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | SaleCommon Stock | 1,211 | $4.72 | $5,715.92 |
DisclosureSEC source: 0000899243-16-032270 · doc4.xml · nonDerivative · entry 1 Neylan John F. · CIK 0001640447 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,556 F1 · price: Sale of a total of 1,211 shares of common stock was made in order to satisfy Dr. Neylan's income tax withholding obligation upon the vesting of 3,750 shares of restricted stock on October 22, 2016. Dr. Neylan had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · balance_after: Includes 76,250 shares of restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.